CFH rs3741775: What Your Genotype Means
The rs3741775 single nucleotide polymorphism is an intronic regulatory variant located within the complement factor H (CFH) gene on chromosome 1. CFH produces a key immune regulatory protein that restrains the alternative complement pathway to protect host tissues. Research has linked variation at rs3741775 to modest differences in complement regulation and susceptibility to age-related maculopathy.
What each genotype means
Typical retinal risk profile
You carry two copies of the common C allele at this CFH regulatory site. Current research provides limited evidence linking this baseline genotype to altered complement activity or elevated macular degeneration risk on its own. Because scientific findings for this specific non-coding site remain modest and often reflect broader regional gene patterns, this genotype alone does not indicate significant vision risk.
Carried by approximately 45% to 50% of individuals of European descent, with varying frequencies across other global ancestries.
Slightly altered complement regulatory profile
You carry one copy of the T alternate allele alongside one standard C allele. In preliminary association studies, this non-coding variant has shown weak statistical connections to complement regulation and retinal outcomes, though current published evidence is limited and inconclusive. Having this single variant copy has not been demonstrated to cause age-related macular changes independently.
Found in roughly 40% to 45% of individuals in European populations, where the minor allele frequency is around 30%.
Altered complement regulatory profile
You carry two copies of the T allele at this CFH regulatory marker. While some research notes modest statistical associations with complement system activity and retinal health in age-related maculopathy, the scientific evidence specifically isolating this non-coding variant remains limited. Carrying this genotype does not mean you will develop vision complications, as retinal health depends heavily on age, lifestyle, and other genetic factors.
Carried by approximately 8% to 10% of individuals of European ancestry and occurs at lower rates in certain non-European groups.
What Is rs3741775 and Where Is It Located?
The single nucleotide polymorphism rs3741775 is situated on the long arm of human chromosome 1 within the CFH locus. Unlike missense mutations that alter amino acid sequences in a protein, rs3741775 is a non-coding regulatory variant located in an intronic segment of the gene. In genomic databases such as dbSNP, it is documented as a single-base transition involving cytosine (C) and thymine (T) alleles. Because it resides outside the protein-coding exons, rs3741775 does not alter the physical structure of the circulating complement factor H protein. Instead, non-coding variants in this region are studied for their potential to influence gene expression levels, transcript splicing, or regulatory element binding. In many genomic studies, intronic variants like rs3741775 are also evaluated as genetic markers that are co-inherited in linkage disequilibrium with other well-characterized regulatory or structural variations across the broader complement factor H gene cluster.
The Biological Function of Complement Factor H
The CFH gene encodes complement factor H, an essential circulating plasma glycoprotein that acts as a major negative regulator of the alternative complement pathway. The complement system is an integral branch of innate immunity that neutralizes invading pathogens, orchestrates inflammatory responses, and clears cellular debris. However, this potent cascade must be tightly restrained to prevent unintended collateral damage to healthy host cells. Factor H fulfills this protective role by binding to C3b, accelerating the breakdown of C3 convertase enzyme complexes, and acting as a cofactor for the cleavage and inactivation of C3b. Host tissues, including the delicate vascular and neurosensory layers of the human retina, display biochemical surface markers that recruit factor H. When complement regulation is impaired or unbalanced, low-grade chronic complement activation can occur, leading to the accumulation of inflammatory debris, microvascular stress, and tissue vulnerability in the eye.
Research on Retinal Health and Age-Related Maculopathy
Scientific investigations into retinal degeneration have repeatedly implicated the CFH genomic region in the pathogenesis of age-related macular degeneration (AMD) and related age-related maculopathies. In the macula, chronic complement dysregulation is believed to promote the formation of drusen, which are extracellular deposits of lipids and inflammatory proteins that accumulate between the retinal pigment epithelium and the choroid. Genetic association studies have identified rs3741775 as a regulatory variant linked to statistical variations in maculopathy risk. However, available scientific evidence specifically isolating rs3741775 remains limited. While major protein-altering polymorphisms such as Tyr402His have established large effect sizes in the scientific literature, non-coding markers like rs3741775 generally exhibit small to modest statistical associations. Many researchers evaluate rs3741775 as part of wider extended haplotypes rather than an independent causal driver of retinal disease.
Navigating Genetic Risk and Clinical Context
Discovering an association between a CFH variant and retinal health often causes concern, but it is crucial to interpret these findings in a proper clinical framework. Single nucleotide polymorphisms like rs3741775 are not diagnostic tests. Age-related maculopathy is a complex, multifactorial disorder influenced by dozens of genomic loci, aging biology, and critical environmental exposures. In particular, lifestyle factors such as cigarette smoking, systemic cardiovascular health, and dietary intake of protective antioxidants play profound roles in individual outcomes. Carrying a statistical risk allele at rs3741775 does not mean that macular degeneration is inevitable, nor does possessing protective alleles guarantee perfect vision. Direct-to-consumer genetic findings should never be used to alter medical regimens or self-prescribe supplements. Individuals with concerns regarding their vision or family history of retinal disorders should seek comprehensive, dilated eye examinations from an optometrist or ophthalmologist.
How common is this variant?
The minor allele frequency for rs3741775 is approximately 0.30 in populations of European ancestry, meaning nearly half of individuals carry at least one copy of the variant allele.
Frequently asked questions
Does carrying the rs3741775 variant mean I will develop macular degeneration?
No, carrying a risk allele at rs3741775 does not mean you will develop macular degeneration. Age-related maculopathy is a complex condition driven by a combination of many genetic variants, aging, and environmental factors like smoking and nutrition. Most individuals with common risk alleles never experience clinically significant vision loss.
What is the difference between rs3741775 and CFH Tyr402His?
While both variants are located in the CFH gene on chromosome 1, Tyr402His (rs1061170) is a coding missense change that directly alters an amino acid in the protein. In contrast, rs3741775 is a non-coding regulatory variant that does not alter protein sequence but may subtly modulate gene regulation or reflect linkage with surrounding variants.
Can I prevent retinal issues if I have a higher-risk genotype?
While you cannot change your inherited genetics, you can modify significant environmental risk factors. Avoiding smoking, wearing UV-protective sunglasses, maintaining cardiovascular health, and eating a diet rich in leafy greens and omega-3 fatty acids are well-established methods to support long-term retinal health.
Should I take vision supplements based on my rs3741775 test result?
You should not start high-dose dietary or vision supplements based solely on an isolated genetic test. The benefits and formulations of specialized eye supplements depend on clinical examination findings, such as the actual presence of drusen, and should only be initiated under the guidance of an eye care professional.
Sources & further reading
Educational information only, last refreshed 9/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3741775?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29